Scholarlink

Background <p>Patient-derived organoids (PDOs) represent a promising approach for replicating the characteristics of original tumors and facilitating drug testing for personalized treatments across diverse cancer types. However, clinical evidence regarding their application to esophageal cancer&#xa0;remains limited. This study aims to evaluate the efficacy of implementing PDOs in clinical practice to benefit patients with esophageal squamous cell carcinoma (ESCC).</p> Methods <p>Fresh surgical biopsies were obtained from patients with esophageal cancer for the establishment of PDOs. These PDOs were subsequently characterized through histological analysis. A customized drug panel, based on standard-of-care chemotherapy regimens, was applied to the PDOs. The resulting drug sensitivity profiles were&#xa0;then correlated with the clinical responses observed in individual patients&#xa0;undergoing actual treatment.</p> Results <p>A total of 34 PDOs were successfully established with a 61.8% success rate. The classification method based on chemotherapy sensitivity closely corresponded to clinical responses. The paclitaxel plus cisplatin (TP)-sensitive group demonstrated significantly longer progression-free survival (PFS) compared to the resistant groups, Hazard ratio&#xa0;(HR), 5.12; 95% confidence intervals (CI 0.58–44.71; p &lt; 0.05), thus illustrating the potential of this approach for guiding personalized treatment strategies.</p> Conclusion <p>Organoid biobanks were established across multiple institutes to facilitate PDOs-based functional precision medicine. The findings demonstrate that this framework offers robust predictive value in clinical settings, enhances precision therapeutics, and advances drug discovery for esophageal cancer.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2024年12月31日

查看全文
  • Suya Shen,
  • Bing Liu,
  • Wenyan Guan,
  • Ziyao Liu,
  • Yuqing Han,
  • Yingzhe Hu,
  • Yiqiang Chen,
  • Siyuan Liu,
  • Jian He,
  • Zhiwen Li,
  • Weifeng Tang,
  • Pengju Zhang,
  • Wei Ren,
  • Yudong Qiu,
  • Hongping Zheng,
  • Jingjing Li

摘要

Background

Patient-derived organoids (PDOs) represent a promising approach for replicating the characteristics of original tumors and facilitating drug testing for personalized treatments across diverse cancer types. However, clinical evidence regarding their application to esophageal cancer remains limited. This study aims to evaluate the efficacy of implementing PDOs in clinical practice to benefit patients with esophageal squamous cell carcinoma (ESCC).

Methods

Fresh surgical biopsies were obtained from patients with esophageal cancer for the establishment of PDOs. These PDOs were subsequently characterized through histological analysis. A customized drug panel, based on standard-of-care chemotherapy regimens, was applied to the PDOs. The resulting drug sensitivity profiles were then correlated with the clinical responses observed in individual patients undergoing actual treatment.

Results

A total of 34 PDOs were successfully established with a 61.8% success rate. The classification method based on chemotherapy sensitivity closely corresponded to clinical responses. The paclitaxel plus cisplatin (TP)-sensitive group demonstrated significantly longer progression-free survival (PFS) compared to the resistant groups, Hazard ratio (HR), 5.12; 95% confidence intervals (CI 0.58–44.71; p < 0.05), thus illustrating the potential of this approach for guiding personalized treatment strategies.

Conclusion

Organoid biobanks were established across multiple institutes to facilitate PDOs-based functional precision medicine. The findings demonstrate that this framework offers robust predictive value in clinical settings, enhances precision therapeutics, and advances drug discovery for esophageal cancer.

Graphical Abstract